Why the study?
Do patients with type 2 diabetes have altered in vivo kinetics of apolipoprotein B-48 and B-100 containing lipoproteins compared to nondiabetic controls?
Population
24 subjects, comprising type 2 diabetic subjects (n=11) and nondiabetic controls (n=13)
Comparison
Primed-constant infusion of l-[5,5,5-D]leucine… vs Nondiabetic controls
Design
Cross-sectional
Follow-up
12 hours
Authors
Loading...
Diabetes-associated TRL overproduction and reduced catabolism may drive dyslipidemia; hypothesis-generating for kinetic-targeted therapies pending prospective trials.
Do patients with type 2 diabetes have altered in vivo kinetics of apolipoprotein B-48 and B-100 containing lipoproteins compared to nondiabetic controls?
Type 2 diabetes is associated with increased production and decreased catabolism of both intestinally derived apoB-48 and hepatic apoB-100 lipoproteins, contributing to triglyceride-rich lipoprotein accumulation.
Hogue et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: